A Phase 3 interventional study of Brimonidine Tartrate and Vehicle in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 4 sites in United States. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-23.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.
Among the 23 studies in Hyperemia with a site in United States, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 3rd registered.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
Browse Hyperemia studies →9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 18+
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Sites in United States
Ages 18–65 · Healthy volunteers
Georgia State University · Sites in United States
Ages 20–59
Georgia State University · Sites in United States
Ages 20–65 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 5 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 68 across 51 interventional studies indexed under Hyperemia.
Median enrollment 68 across the 19 interventional studies, 40 across the 4 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
Bausch Health Companies Inc. has 3 studies filed under Hyperemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07578363Phase 3Alcon ResearchAn Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | 2026-11 |
| NCT07531043Phase 3Alcon ResearchEfficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | 2027-02 |
| NCT07209410Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma | 2026-12-15 |
| NCT06735599Georgia State UniversityWild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure | 2027-01-01 |
| NCT06735651Georgia State UniversityWild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies in Hyperemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
Drug: Brimonidine Tartrate · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
Drug: Vehicle · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Ophthalmic solution to be applied as directed.
Ophthalmic solution to be applied as directed.
For use as needed during the study for evaluating corneal damage.
For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Day 29
Drop Comfort Assessment as Assessed by the Participant
Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participant. Participant's average score across eyes at each time point were used for analysis.
Time frame: At dose installation, 30 seconds postdose installation, and 1 minute postdose installation on Day 1
Number of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29
An alertness evaluation was performed by the Investigator asking the participant and/or participant's parent/legal guardian (pediatric participants only) a few questions based on the previous week. Using those answers, along with his/her clinical opinion, the Investigator made an assessment of the participant's level of alertness using the following 6-point scale: fully alert, alert, lethargy, obtunded, stupor, or coma.
Time frame: Predose installation on Day 1 and 90-180 minutes postdose installation on Days 1, 8, 15, and 29
| Milestone | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Started | 337 | 170 |
| Received at least 1 dose of study drug | 337 | 170 |
| Completed | 324 | 166 |
| Not completed | 13 | 4 |
| Withdrew: Investigator decision | 3 | 0 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Administrative reasons | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 |
TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Participants with at Least 1 TEAE | 66 | 38 |
| Participants with at Least 1 Ocular TEAE | 44 | 25 |
| Participants with at least 1 Non-Ocular TEAE | 23 | 16 |
| Participants with at least 1 Serious TEAE | 2 | 0 |
| Participants Discontinued from Study due to TEAEs | 5 | 2 |
Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participant. Participant's average score across eyes at each time point were used for analysis.
| units on a scale | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Upon Dose Installation | 0.4 ± 0.90 | 0.4 ± 0.77 |
| 30 Seconds Postdose Installation | 0.4 ± 0.90 | 0.3 ± 0.85 |
| 1 Minute Postdose Installation | 0.4 ± 0.83 | 0.4 ± 0.83 |
An alertness evaluation was performed by the Investigator asking the participant and/or participant's parent/legal guardian (pediatric participants only) a few questions based on the previous week. Using those answers, along with his/her clinical opinion, the Investigator made an assessment of the participant's level of alertness using the following 6-point scale: fully alert, alert, lethargy, obtunded, stupor, or coma.
| Participants | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Predose Installation on Day 1 | 337 | 170 |
| Postdose Installation on Day 1 | 336 | 169 |
| Postdose Installation on Day 8 | 326 | 167 |
| Postdose Installation on Day 15 | 326 | 166 |
| Postdose Installation on Day 29 | 323 | 164 |
Collected over Baseline up to Day 29. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine Tartrate | — | 2/337 (0.6%) | 27/337 (8%) |
| Brimonidine Tartrate Vehicle | — | 0/170 (0%) | 14/170 (8.2%) |
| Event | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| GastroenteritisInfections and infestations | 1/337 | 0/170 |
| Staphylococcal infectionInfections and infestations | 1/337 | 0/170 |
| SinusitisInfections and infestations | 1/337 | 0/170 |
| Event | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Visual Acuity ReducedEye disorders | 16/337 | 9/170 |
| Conjunctival HyperaemiaEye disorders | 11/337 | 6/170 |
All randomized participants who received at least 1 dose of study drug (Safety Population).
| Age, Continuous(years) | Brimonidine Tartrate | Brimonidine Tartrate Vehicle | Total |
|---|---|---|---|
| Mean | 40.7 ± 17.13 | 41.0 ± 17.68 | 40.8 ± 17.30 |
| Sex: Female, Male(Participants) | Brimonidine Tartrate | Brimonidine Tartrate Vehicle | Total |
|---|---|---|---|
| Female | 200 | 100 | 300 |
| Male | 137 | 70 | 207 |
Ran from Feb 2014 to primary completion in Apr 2014, 2 months.
Results were first posted in Oct 2019, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine